Drug Trial Radar · NCT07308782
A Phase Ⅱa Clinical Study of CL-197 Capsules
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Nov 29, 2025
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Henan Genuine Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the antiretroviral activity, safety and pharmacokinetics of single dose of CL-197 capsule in three dose groups administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.
Conditions
- HIV-1 Infection
Interventions
CL-197 capsulesDrug
Participants will take a single dose of CL-197 capsules at a dose of 10 mg, 30 mg or 60 mg, orally on an empty stomach.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in log10 value of HIV-1 Ribonucleic acid (RNA) on Day 8Time frame: Baseline and Day 8.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Youan Hospital, Capital Medical University
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.